Evidence map›Paper›PMID 29486724›Full record

ArticleBMC nephrology2018

A case of ureteral myeloid sarcoma post-renal transplantation.

Liang Ying, Lei Tian, Yuanyuan Xie, Qin Wang, Xiajing Che, Jiayi Yan, Lijing Shen, Honghui Huang, Fangyuan Chen, Ming Zhang and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Liang YingDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.
Lei TianDepartment of Nephrology, Molecular Cell Laboratory for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Center for Peritoneal Dialysis Research, Shanghai Jiaotong University, Shanghai, 200127, People's Republic of China.
Yuanyuan XieDepartment of Nephrology, Molecular Cell Laboratory for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Center for Peritoneal Dialysis Research, Shanghai Jiaotong University, Shanghai, 200127, People's Republic of China.
Qin WangDepartment of Nephrology, Molecular Cell Laboratory for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Center for Peritoneal Dialysis Research, Shanghai Jiaotong University, Shanghai, 200127, People's Republic of China.
Xiajing CheDepartment of Nephrology, Molecular Cell Laboratory for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Center for Peritoneal Dialysis Research, Shanghai Jiaotong University, Shanghai, 200127, People's Republic of China.
Jiayi YanDepartment of Nephrology, Molecular Cell Laboratory for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Center for Peritoneal Dialysis Research, Shanghai Jiaotong University, Shanghai, 200127, People's Republic of China.
Lijing ShenDepartment of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.
Honghui HuangDepartment of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.
Fangyuan ChenDepartment of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.
Ming ZhangDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.
Zhaohui NiDepartment of Nephrology, Molecular Cell Laboratory for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Center for Peritoneal Dialysis Research, Shanghai Jiaotong University, Shanghai, 200127, People's Republic of China. profnizh@126.com.
Shan MouDepartment of Nephrology, Molecular Cell Laboratory for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Center for Peritoneal Dialysis Research, Shanghai Jiaotong University, Shanghai, 200127, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSignificant attention has been directed toward the high incidence of malignant tumours that occur post-transplantation. However, there are few reports of myeloid sarcomas (MSs) following renal transplantation. CASE PRESENTATION: This case report describes a 26-year-old male patient who presented with repeatedly high creatinine levels and hydronephrosis six months post-renal transplantation. Surgical pathology revealed ureteral MS; however, the tumour recurred following resection. Bone marrow biopsy indicated that the patient also had acute promyelocytic leukaemia. The tumour was treated with local radiotherapy, and the leukaemia was treated with systemic chemotherapy. The patient's conditions were satisfactory at the one-year follow-up.

conclusionsThis report is the first to describe a ureteral MS post-renal transplantation. Our findings suggest that surgical resection combined with radiotherapy and chemotherapy can help control the status of patients with this condition.

Indexed as

AdultFollow-Up StudiesHumansHydronephrosisKidney TransplantationMaleNeoplasm Recurrence, LocalSarcoma, MyeloidUreteral NeoplasmsAcute myeloid leukaemiaMyeloid sarcomaRenal transplantation

Identifiers

PMID29486724
PMCPMC5830329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.